The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Should HR-SMM be treated before progression to NDMM?
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses early intervention for high-risk smoldering multiple myeloma (HR-SMM) before progression to newly diagnosed multiple myeloma (NDMM). He mentions a Phase II trial (NCT01572480) revealing high measurable residual disease (MRD) negativity rates in patients with HR-SMM treated with carfilzomib, lenalidomide, and dexamethasone (KRd), followed by lenalidomide maintenance, sustained over an 8-year follow-up. Whole genome sequencing (WGS) indicates that HR-SMM is less genomically evolved than NDMM, suggesting that early detection and initiation of therapy before symptoms could prevent progression. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Honoraria: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on an entity’s Board of Directors or advisory committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex; Membership on independent data monitoring committees: Merck, Amgen, Takeda, Janssen, Celgene, Adaptive, Theradex.
